Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.33 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515031 | 0.90 | MLYCD (0.36) | TRPM8MLYCDALDH1A1CYP3A4LPAR5 | |
| SCHEMBL28974225 | 0.83 | KMT2A (0.43) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL26127613 | 0.79 | CLK1 (0.45) | ALDH1A1CYP3A4LPAR5KDM4EHPGD | |
| SCHEMBL26128828 | 0.78 | MLYCD (0.35) | TRPM8MLYCDALDH1A1LPAR5KDM4E | |
| SCHEMBL26128304 | 0.78 | CLK1 (0.41) | ALDH1A1LPAR5KDM4EHPGDGAA | |
| SCHEMBL3983002 | 0.77 | NR4A2 (0.50) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL26125608 | 0.76 | LPAR5 (0.40) | LPAR5GAAHTTPOLBCLK1 | |
| SCHEMBL9231407 | 0.74 | BAZ2B (0.41) | ALDH1A1KDM4EHPGDGAAPOLB | |
| SCHEMBL27516303 | 0.74 | FNTA (0.39) | ALDH1A1CYP3A4KDM4EHPGDGAA | |
| SCHEMBL18137568 | 0.74 | QPCT (0.44) | TRPM8MLYCDALDH1A1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042900-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4499058-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | Tactogen Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4426291-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | PNMT, HTR5A, HTR4 | TRPM8 506/4885MLYCD 1067/4885ALDH1A1 4486/4885 |
| US-20250042900-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TPH2, TPH1, IDO2 | TRPM8 1083/4885MLYCD 638/4885ALDH1A1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.